Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
- Other Names / Subsidiaries
- Xiangxue Pharmaceuticals, Co., Ltd
- Xiangxue Life Sciences